CLINICAL AND MORPHOLOGICAL CHARACTERISTICS OF PANCREATIC CANCER ACCORDING TO AUTOPSY FINDINGS
Abstract
Background. Over the past decades, the incidence of pancreatic cancer (PCa) has been on the rise. It is characterized by a long latent course, non-specificity of clinical symptoms, a tendency to early metastasis, and limited possibilities for biopsy. The survival rate of patients with pancreatic cancer within a year after its diagnosis is no more than 8%.
Objective. To study the clinical and morphological features of pancreatic cancer and to assess the state of life-time diagnosis according to autopsy findings.
Material and methods. A retrospective analysis of 58 autopsy protocols of patients died due to pancreatic cancer was carried out. The protocols of autopsies as well as micropreparations of the pancreas and other various organs taken during autopsy for histopathological examination were studied.
Results. Among those who died due to pancreatic cancer there were 58.6% of men and 41.4% of women. The average age of males was 68.9 years, that of females - 67.0 years. The discrepancy between the pathoanatomical and clinical diagnoses was noted in 7.7% of cases. Chronic pancreatitis as a background disease occurred in 6.9% of cases of pancreatic cancer. A nodular form of cancer growth was detected in 87.9%, a diffuse-infiltrative one - in 12.1% of cases. In 81.0% of cases, the tumor was localized in one of the pancreatic sections, in 19.0% - in several ones. Cancer of the pancreatic head occurred in 72.4% of cases; in 5.2% of cases the tumor was localized only in the tail, in 3.4% - only in the body of the gland. The body and tail of the pancreas were involved in the tumor process in 10.3%, while the head and body in 5.2% of cases. In 3.5% of cases, the tumor completely infiltrated the pancreas.
Conclusions. Radical surgical interventions were performed only in 20.7% of cases. They were performed in 28.6% of cases in patients with pancreatic head tumours. In case of tumour location in the distal parts of the pancreas, such interventions were impossible due to the presence of multiple metastases. In 7.7% of cases, the diagnosis of pancreatic cancer was established only at autopsy.
References
Cimmerman JaS. Rak podzheludochnoj zhelezy: terra incognita sovremennoj mediciny [Pancreatic cancer: terra incognita in modern gastroenterology]. Klinicheskaja medicina [Clinical Medicine]. 2015;93(10):5-13. (Russian).
Kaprin AD, Starinskij VV, Petrov GV, editors. Zlokachestvennye novoobrazovanija v Rossii v 2018 godu (zabolevaemost i smertnost). Moskva: MNIOI im. P.A. Gercena - filial FGBU "NMIC radiologii" Minzdrava Rossii; 2019. 250 р. (Russian).
Koshel AP, Klokov SS, Mironova EB, Sevast'janova HV. Rak podzheludochnoj zhelezy: nekotorye voprosy diagnostiki i lechenija. Vestnik Kluba Pankreatologov [Herald Pancreatic Club]. 2010;2(7):19-22. (Russian).
Vasilenko VH, Lemeshko ZA. O diagnostike raka podzheludochnoj zhelezy. Klinicheskaja medicina [Clinical Medicine]. 1984;62(10):131-137. (Russian).
Gress TM, Neoptolemos JP, Lemoine NR, Real FX, editors. Exocrine Pancreas Cancer: The European Pancreatic Cancer-Research Cooperative (EPS - RC). Hannover; 2005. 531 p.
Putov NV, Artemeva NN, Kohanenko NJu. Rak podzheludochnoj zhelezy [Pancreatic cancer]. Sankt-Peterburg: Piter; 2005. 396 p. (Russian).
Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. eta-analysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008;8:82. https://doi.org/10.1186/1471-2407-8-82
Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP. Phase III randomized comparison of gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2009;27(33):5513-5518. https://doi.org/10.1200/JCO.2009.24.2446
Stocken DD, Büchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Neoptolemos JP. Meta-analysis of randomized adjuvant therapy trials for pancreatic cancer. Br. J. Cancer. 2005;92(8):1372-1381. https://doi.org/10.1038/sj.bjc.6602513
Rocca G, Gaia E, Iuliano R, Caselle MT, Rocca N, Calcamuggi G, Emanuelli G. Increased incidence of cancer in chronic pancreatitis. J. Clin. Gastroenterol. 1987;9(2):175-179. https://doi.org/10.1097/00004836-198704000-00013
Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andrén-Sandberg A, Domellöf L. Pancreatitis in the risk of pancreatic cancer. N. Engl. J. Med. 1993;328(20):1433-1437. https://doi.org/10.1056/NEJM199305203282001
Lazebnik LB, Vinokurova LV, Jashina NI, Bystrovskaja EV, Bordin DS, Dubcova EA, Orlova JuN. Hronicheskij pankreatit i rak podzheludochnoj zhelezy [Chronic pancreatitis and pancreatic cancer]. Vestnik Kluba Pankreatologov [Herald Pancreatic Club]. 2014;1(22):39-44. (Russian).
Komarova FI, Rapoporta SI, editors. Rukovodstvo po gastrojenterologii. Moskva: "OOO Med. Inform. agentstvo"; 2010. 864 р. (Russian).
Rieder H, Bartsch DK. Familial pancreatic cancer. Fam. Cancer. 2004;3(1):69-74. https://doi.org/10.1023/B:FAME.0000026822.67291.a1
Delpu YN, Hanoun H, Lulka H, Sicard F. Genetic and epigenetic alterations in pancreatic cancerogenesis. Curr. Genom. 2011;12(1):15-24. https://doi.org/10.2174/138920211794520132
Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol. 2009;6(2):699-708. doi: 10.1038/nrgastro.2009.177. https://doi.org/10.1038/nrgastro.2009.177
Wolpin BM, Ng K, Bao Y, Kraft P, Stampfer MJ, Michaud DS, Ma J, Buring JE, Sesso HD, Lee IM, Rifai N, Cochrane BB, Wactawski-Wende J, Chlebowski RT, Willett WC, Manson JE, Giovannucci EL, Fuchs CS. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(1):82-91. https://doi.org/10.1158/1055-9965.EPI-11-0836
Duell EJ, Lucenteforte E, Olson SH, Bracci PM, Li D, Risch HA, Silverman DT, Ji BT, Gallinger S, Holly EA, Fontham EH, Maisonneuve P, Bueno-de-Mesquita HB, Ghadirian P, Kurtz RC, Ludwig E, Yu H, Lowenfels AB, Seminara D, Petersen GM, La Vecchia C, Boffetta P. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol. 2012;23(11):2964-2970. https://doi.org/10.1093/annonc/mds140
Makohon-Moore A, Iacobuzio-Donahue CA. Pancreatic cancer biology and genetics from an evolutionary perspective. Nat. Rev. Cancer. 2016;16(9):553-565. https://doi.org/10.1038/nrc.2016.66
Pandit S, Samant H, Kohli K, Shokouh-Amiri HM, Wellman G, Zibari GB. Incidental liver metastasis in pancreatic adenocarcinoma. Journal of Surgical Case Reports. 2019;2019(3):rjs084. https://doi.org/10.1093/jscr/rjz084
Ansari D, Friess H, Bauden M, Samnegård J, Andersson R. Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment. Oncotarget. 2018;9(5):6644-6651. https://doi.org/10.18632/oncotarget.24019
Kraevskij NA, Smoljannikov AV, Sarkisov DS, editors. Patologoanatomicheskaja diagnostika opuholej cheloveka. Vol. 2. Moskva: Medicina; 1993. 688 p. (Russian).
Popovich AJu. Rak podzheludochnoj zhelezy [Pancreatic cancer]. Vestnik Kluba Pankreatologov [Herald Pancreatic Club]. 2009;3:31-39. (Russian).
Gubergric NB, Golubova OA. Hronicheskij pankreatit, kak predrakovoe zabolevanie [Chronic pancreatitis as pre-cancer disease]. Vestnik Kluba Pankreatologov [Herald Pancreatic Club]. 2009;4:36-41. (Russian).
Cavastro GM, Giuseppe C, Nouvenne A, Sianesi M. The race from chronic pancreatitis to pancreatic cancer. JOP J. Pancreas. 2003;4(5):165-168.
Johnson PT, Outwater EK. Pancreatic carcinoma versus chronic pancreatitis: Dinamic MR imaging. Radiology. 1999;212(1):213-218. https://doi.org/10.1148/radiology.212.1.r99jl16213
Bardeesy N, De Pinho RA. Pancreatic cancer biology and genetics. Nat. Rev. Cancer. 2002;2(12):897-909. https://doi.org/10.1038/nrc949
Lahdaoui F, Delpu Y, Vincent A, Renaud F, Messager M, Duchêne B, Leteurtre E, Mariette C, Torrisani J, Jonckheere N, Van Seuningen I. miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer. Oncogene. 2015;34(6):780-788. https://doi.org/10.1038/onc.2014.11
Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE. P53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994;54(11):3025-3033.
Gerdes B, Ramaswamy A, Kersting М, Ernst M, Lang S, Schuermann M, Wild A, Bartsch DK. P16 (INK4a) alterations in chronic pancreatitis - indicator for high-risk lesions for pancreatic cancer. Surgery. 2001;129(4):490-497. https://doi.org/10.1067/msy.2001.112071
Khan MA, Azim S, Zubair H, Bhardwaj A, Patel GK, Khushman M, Singh S, Singh AP. Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. Int. J. Mol. Sci. 2017;18(4):779. https://doi.org/10.3390/ijms18040779
Fletcher СDM, editor. Diagnostic histopathology of tumors. Vol. 1. London: Churchill LivingstoneEdinburg; 2000. 930 p.
1.png)
